Cardiac Magnetic Resonance Assessment of Interstitial Myocardial Fibrosis and Cardiomyocyte Hypertrophy in Hypertensive Mice Treated With Spironolactone

Citation

Published Version
doi:10.1161/JAHA.114.000790

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890613

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Cardiac Magnetic Resonance Assessment of Interstitial Myocardial Fibrosis and Cardiomyocyte Hypertrophy in Hypertensive Mice Treated With Spironolactone

Otavio R. Coelho-Filho, MD, MPH;* Ravi V. Shah, MD;* Tomas G. Neillan, MD; Richard Mitchell, MD, PhD; Heitor Moreno, Jr, MD, PhD; Raymond Kwong, MD, MPH; Michael Jerosch-Herold, PhD

Background—Nearly 50% of patients with heart failure (HF) have preserved LV ejection fraction, with interstitial fibrosis and cardiomyocyte hypertrophy as early manifestations of pressure overload. However, methods to assess both tissue characteristics dynamically and noninvasively with therapy are lacking. We measured the effects of mineralocorticoid receptor blockade on tissue phenotypes in LV pressure overload using cardiac magnetic resonance (CMR).

Methods and Results—Mice were randomized to l-nitro-o-methyl ester (l-NAME, 3 mg/mL in water; n=22), or l-NAME with spironolactone (50 mg/kg/day in subcutaneous pellets; n=21). Myocardial extracellular volume (ECV; marker of diffuse interstitial fibrosis) and the intracellular lifetime of water (τic; marker of cardiomyocyte hypertrophy) were determined by CMR T1 imaging at baseline and after 7 weeks of therapy alongside histological assessments. Administration of l-NAME induced hypertensive heart disease in mice, with increases in mean arterial pressure, LV mass, ECV, and τic compared with placebo-treated controls, while LV ejection fraction was preserved (>50%). In comparison, animals receiving both spironolactone and l-NAME (“l-NAME+S”) showed less eccentric remodeling, and a lower myocardial ECV and τic, indicating decreased interstitial fibrosis and cardiomyocyte hypertrophy (ECV: 0.43±0.09 for l-NAME versus 0.25±0.03 for l-NAME+S, P<0.001; τic: 0.42±0.11 for l-NAME groups versus 0.12±0.05 for l-NAME+S group). Mice treated with a combination of l-NAME and spironolactone were similar to placebo-treated controls at 7 weeks.

Conclusions—Spironolactone attenuates interstitial fibrosis and cardiomyocyte hypertrophy in hypertensive heart disease. CMR can phenotype myocardial tissue remodeling in pressure-overload, furthering our understanding of HF progression. (J Am Heart Assoc. 2014;3:e000790 doi: 10.1161/JAHA.114.000790)

Key Words: cardiac magnetic resonance imaging • hypertension • hypertrophy/remodeling

Nearly 50% of incident heart failure occurs in the presence of preserved left ventricular ejection fraction (HF-pEF). In patients with HF-pEF, both cardiomyocyte hypertrophy and elevated interstitial myocardial collagen content are prominent features of tissue remodeling.

However, therapies specifically directed at interstitial fibrosis and hypertrophy (eg, phosphodiesterase-5 inhibition and spironolactone) have had limited efficacy in treating HF-pEF, possibly due to late application of therapies (eg, after development of irreversible tissue-level changes). Furthermore, reliance on LV hypertrophy (LVH) and its regression to stratify risk has limitations: regression of LVH (by blood pressure control) does not fully normalize cardiac prognosis or incident HF. In this context, assessing tissue fibrosis and cardiomyocyte hypertrophy non-invasively in pathologic LV remodeling – specifically alongside therapies that target these key pathologies – would be fundamental to pre-clinical drug development in HF-pEF, and for targeting patients with greatest potential benefit.

Given the importance of fibrosis as a target for prevention at the transition to HF-pEF, increasing clinical interest has focused on the use of mineralocorticoid receptor (MR) antagonist therapy in the treatment of HF-pEF. In animal models of pressure-overload hypertrophy, spironolactone prevents interstitial fibrosis, cellular and organ-level hypertrophy, and...
Spironolactone Prevents Fibrosis and Hypertrophy

Coelho-Filho et al

spironolactone prevents development of HF. Although MR antagonism leads to regression of LV hypertrophy in hypertensive individuals,10,11 there are conflicting results on the clinical and physiological benefits of spironolactone in established HF-pEF.5,12

In this study, we developed a noninvasive CMR-based technique to measure the modifiability of myocardial tissue phenotypes in mice during the induction of hypertension (via L-nitro-ω-methyl ester/L-NAME-treated mice), a well-established model of hypertensive heart disease and HF-pEF. This study extends our method to phenotype fibrosis and cardiomyocyte hypertrophy concurrently with a therapy—the first step in translating this imaging technique to human applications in HF-pEF.

Methods

Animal Models

Wild-type mice (mean body weight 37.8±6.4 g, Taconic) were randomly assigned to 2 experimental groups: (1) L-NAME (“L-NAME”; n=22), which included L-NAME in the drinking water (3 mg/mL; Sigma, USA) for 7 weeks, and (2) L-NAME and spironolactone (“L-NAME+S”; n=21) with L-NAME (3 mg/mL; Sigma, USA) in the drinking water, and spironolactone (50 mg/kg per day) delivered by subcutaneous pellets (Innovative Research of America) implanted in the subcapsular region as previously described.13,14 (Animals in the L-NAME group did not have subcutaneous pellets.) Animals were kept under standard conditions with normal chow and water ad libitum. Noninvasive tail blood pressures were obtained at baseline and after 7 weeks of treatment using a volume-pressure recording tail-cuff technique15 (CODA-1, Kent Scientific). CMR was performed at baseline and after 7 weeks of treatment (L-NAME and L-NAME+S). Blood samples were collected immediately after each CMR study for blood hematocrit determination (l-STAT). Animals were euthanized following the second CMR study, and the hearts were excised for histological analysis. The same strain of mice, undergoing the same experimental protocol as the L-NAME group, but receiving only tap water instead of spironolactone in established HF-pEF,5,12 the cell membrane were used for cardiomyocyte size determination.17 All sections were scanned with ScanScope scanners (Aperio Technologies, Inc), and whole-slide images were sampled to a final resolution of 1.0 µm/pixel. Measurements of (minor) cardiomyocyte diameter Dmin and major cardiomyocyte-diameter Dmaj (equivalent to the cardiomyocyte length) were obtained by image analysis of FITC-wheat germ agglutinin stained sections. Ten measurements of Dmaj and Dmin were made in each of the anterior, septal, lateral, and inferior wall sections of the left ventricle. Cardiomyocyte volume was calculated assuming a cell shape in the form of a prolate ellipsoid,18-21 using the median Dmin and Dmaj. Connective tissue volume fraction was quantified on sections stained with Masson’s trichrome stain, using a semi-automatic pixel color intensity algorithm in the Aperio Spectrum software to quantify pixels stained in blue.

Cardiac Magnetic Resonance Imaging

Anesthetized mice (isofluorane=1% to 2.5% in oxygen from a precision vaporizer) were positioned prone in a water-heated cradle in a dedicated MRI system for small animal imaging (4.7 T Bruker BioSpin). Cine CMR images were acquired with prospective electrocardiographic and respiratory gating (model 1025L, SAII). For left ventricular (LV) size and function, short-axis cine fast gradient echo images were acquired with full ventricular coverage (repetition time TR 5.9 ms; echo time TE 2.2 ms; temporal resolution 12 to 15 ms; in-plane spatial resolution 100 to 120 µm×180 to 210 µm; 1 mm slice thickness, no gap). Simpson’s rule was used to calculate LV volumes, mass, and LV ejection fraction (LVEF). LV volumes and mass were indexed by body weight. Gadolinium diethylenetriamine-pentacetic acid (Magnevist, Berlex) was administered subcutaneously in multiple stages up to a cumulative dose of 0.5 mmol/kg. Myocardial and blood T1s were measured in a mid short-axis slice once precontrast, and at least 4 times postcontrast using a Look-Locker technique, and no earlier than 4 minutes after contrast administration as described previously22 (TR 2.5 ms; TE 1.8 ms; flip angle=10°, in-plane resolution 190 µm, 1 mm slice thickness). Signal intensity versus time curves were used to determine T1 by non-linear least-squares fitting to an analytical expression for the magnitude signal measured during the inversion recovery,22 and correction for the radiofrequency pulse effects on the inversion recovery.23

The reciprocal of T1 (R1=1/T1) for each myocardial segment was analyzed as a function of R1 in the blood pool. Myocardial R1, shows a sublinear dependence on R1 in blood when the relaxation rate in blood approaches the rate of exchange of water across the transcytolemmal barrier (on the order of 1/τw)—the rate of water exchange across the cell membrane then effectively becomes a bottleneck for further
increases of the myocardial R1. This allows a determination of the intracellular lifetime, using as model a 2-space water-exchange (2SX) model of equilibrium transcytosomeal water exchange to obtain myocardial extracellular volume (ECV) and the intracellular lifetime of water \( \tau_{ic} \). ECV and \( \tau_{ic} \) were both independent parameters of the 2SX model.\textsuperscript{16,22,24}

The intracellular lifetime of water, \( \tau_{ic} \) depends on the mean time for a water molecule to diffuse to the cell membrane. It can be shown that \( \tau_{ic} \) is proportional to the volume-to-surface ratio \( V/S \),\textsuperscript{24,25} with \( V/S \) being on the order of the cell diameter in the case of cardiomyocytes, which have a length-to-diameter ratio of \( \approx 4:1 \). This means that with the elongated shape of cardiomyocytes, the intracellular lifetime is primarily sensitive to changes in cell diameter.\textsuperscript{16}

Statistical Analyses

Statistical analysis was performed using SAS 9.3 (SAS Institute) or R (version 3.0.1, R Foundation; http://www.R-project.org/). Data are presented as means\( \pm \)standard deviation. Continuous variables were compared between the 2 L-NAME-treated groups of mice using \( t \) tests. Linear mixed effects (LME) regression models (using package “lme4” in R) were built for variables with repeated measures (eg, ECV and LV parameters) to test the effects of treatment and time (ie, difference between baseline and follow-up). Experimental group, study time-point (baseline or follow-up), and their interaction were included as fixed effects in each LME model. A random mouse-specific intercept accounted for correlations of measurements within each mouse. For variables with repeated measurements \( P \) values are for comparisons of least squares means for the factors of said linear mixed effects models (using package “HonestSignificantDifference” in R). Therefore, for each variable with repeated measurements, one and the same linear mixed effects model was used to obtain \( P \) values for comparisons between groups at baseline and at follow-up, and for comparisons within a group between baseline and follow-up. For the histological variables with only one measurement per animal, \( P \) values were obtained by Tukey’s “Honest Significant Difference” Method. Linear correlations were assessed by Pearson’s correlation coefficient. Multivariate linear regression models were built for myocardial ECV and intracellular lifetime of water \( \tau_{ic} \) to test whether at follow-up the treatment effect of spironolactone was significant, with simultaneous adjustment by mean arterial pressure.

Results

LV Hypertrophy, Fibrosis and Cardiomyocyte Hypertrophy From L-NAME

Table summarizes the hemodynamic, CMR, and histological parameters at baseline and after 7 weeks of L-NAME therapy with and without spironolactone. An example of how the T1 measurements allowed the simultaneous determination of ECV and intracellular lifetime is shown in Figure 1. There were no significant differences in cardiac structure, function, or CMR-derived tissue phenotype (by intracellular lifetime of water or ECV shown in Figures 2 and 3) at baseline between the 2 groups. (There were also no significant differences at baseline when the controls were included.) Administration of L-NAME induced hypertension,\textsuperscript{26–28} as expected, with an increase in mean arterial pressure from 86.8±7.4 mm Hg at baseline to 124.4±6.1 mm Hg after 7 weeks of L-NAME therapy (\( P<0.001 \)). In response to hypertension, LV mass increased in mice treated with L-NAME (163±19 \( \mu \)g for L-NAME versus 99±14 \( \mu \)g for placebo-treated controls, \( P<0.001 \)), accompanied by a modest decrease in LV systolic function (LVEF 51±8% for L-NAME versus 60±3% for controls, \( P<0.001 \)). LV mass-to-volume increased in L-NAME treated mice (concentric remodeling). There were no significant changes in indexed LV mass or function in the control group.

The myocardial ECV, a CMR marker of interstitial fibrosis, increased after 7 weeks of L-NAME treatment (0.43±0.09 in L-NAME at follow-up versus 0.26±0.03 in controls at follow-up, \( P<0.001 \)). The intracellular lifetime of water by CMR \( \tau_{ic} \), a marker of cardiomyocyte hypertrophy, was increased after 7 weeks of L-NAME as compared with controls (0.42±0.11 for L-NAME versus 0.18±0.08 versus controls, \( P<0.001 \)).

Effects of Spironolactone on Interstitial Fibrosis and Cardiomyocyte Hypertrophy

Spironolactone treatment successfully abrogated the development of hypertension and hypertensive heart disease in animals treated with L-NAME, with a reduction in mean arterial pressure and LV mass relative to mice receiving solely L-NAME (Table). In comparison with L-NAME-treated mice, animals receiving both spironolactone and L-NAME showed a lower myocardial ECV and \( \tau_{ic} \), indicating decreased interstitial fibrosis and cardiomyocyte hypertrophy (myocardial ECV: 0.43±0.09 for L-NAME versus 0.25±0.03 for L-NAME+S, \( P<0.001 \); \( \tau_{ic} \): 0.42±0.11 for L-NAME groups versus 0.12±0.05 for L-NAME+S group). Indeed, at follow-up, myocardial ECV and \( \tau_{ic} \) in mice receiving both L-NAME and spironolactone were not significantly different from controls (Figures 2 and 3). The differences in ECV and \( \tau_{ic} \) between L-NAME and L-NAME+S groups remained highly significant at follow-up when adjusted by the baseline measurements, using a LME model, and this also remained the case when the control group was included. The on-therapy effect of spironolactone on myocardial ECV and \( \tau_{ic} \) remained significant after adjustment for mean arterial pressure in linear regression (myocardial ECV: multiple \( R^2 \) adjusted to MAP=0.71, \( P<0.001 \); \( \tau_{ic} \): multiple \( R^2 \) adjusted to MAP=0.77, \( P<0.001 \)). Concomitant administration of spironolactone and L-NAME returned the
myocardial tissue phenotype to that seen in controls when measured by histology or CMR.

ECV correlated strongly with the LV mass-to-volume ratio, a marker of concentric remodeling ($r=0.62$, $P<0.001$). The marker of cardiomyocyte hypertrophy, $\tau_{vc}$, also correlated with LV mass-to-volume ratio ($r=0.54$, $P<0.001$).

### Histological Measurements and Relation to CMR Markers

The histological measurements of connective tissue volume fraction and the cardiomyocyte volume-to-surface ratio (Figure 4), showed changes between groups, which paralleled the differences for ECV and $\tau_{vc}$, respectively. Overall, there was a strong association between ECV and histological fibrosis ($r=0.879$, $P<0.01$; Figure 5A), and between $\tau_{vc}$ and cardiomyocyte (minor) diameter ($r=0.892$, $P<0.01$; Figure 5B). Mice treated with $\text{L-NAME}$ alone averaged the highest volume-to-surface ratio (32.1 ± 1.9 in $\text{L-NAME}$ at follow-up versus 24.7 ± 1.5 in controls, $P<0.001$, and also versus 25.3 ± 1.4 in $\text{L-NAME+S}$, $P<0.001$), and the highest cardiomyocyte volume (77.4 ± 12.9 in $\text{L-NAME}$ versus 42.3 ± 6.1 in controls, $P<0.001$ and also versus, 47 ± 6 in $\text{L-NAME+S}$, $P<0.001$), paralleling the increase of ECV and $\tau_{vc}$ between $\text{L-NAME+S}$ and $\text{L-NAME}$ groups.

### Discussion

The principal finding of our study is that CMR measurements of extracellular volume fraction and intracellular lifetime of water sensitively track changes in tissue phenotype with anti-remodeling therapy in a mouse model of hypertensive heart disease. This work extends previous results from our laboratory validating ECV and $\tau_{vc}$ in pressure overload$^{16,22}$ by demonstrating the modifiability of these indices with inter-
Interventions aimed at tissue remodeling in the hypertensive heart. When added to L-NAME therapy, spironolactone blocked the increase in myocardial ECV and $s$ observed with L-NAME therapy alone. Importantly, these changes were independent of on-therapy reduction in blood pressure in mice treated with spironolactone, and occurred in the presence of a clinically normal LV ejection fraction (mean LVEF>50% in all groups). Collectively, these results establish the utility of CMR imaging to diagnose phenotypes during the transition from hypertensive heart disease to HF-pEF.

Hypertension is the strongest modifiable risk factor for development of HF and subsequent cardiac mortality. In animal models, afterload excess from hypertension engenders a characteristic genetic and morphologic ventricular response, from cellular and organ-level hypertrophy and interstitial fibrosis to ultimate ventricular dilatation and failure. Specifically, interstitial fibrosis may mark the transition from compensated cellular and organ-level pathologic hypertrophy to HF in both animals and at-risk patients. However, a residual risk of HF in patients after regression of LVH remains, suggesting the presence of adverse, tissue-level phenotypes beyond LVH. In addition, the limited benefit of novel, anti-fibrotic therapies in older patients with long-standing hypertension and established HF-pEF further suggests that demonstrating the benefits of anti-fibrotic therapies earlier in the course of HF (eg, stage A HF) may be critical.

The imperative to identify early phenotypes in the progression to HF has partially motivated recent work utilizing T1 mapping CMR to examine interstitial fibrosis in pressure overload. In a study of 10 rats exposed to angiotensin II to promote LVH, Messroghli and colleagues used Look-Locker inversion recovery T1 mapping to demonstrate elevated ECV in parallel to histologic fibrosis after induction of hypertension. Our group has published data demonstrating increased ECV in mice exposed to pharmacologically induced hypertension (eg, L-NAME) and mechanical pressure overload (eg, transverse

**Figure 1.** Illustration of dependence of myocardial R1 on R1 in blood. This example is from a study in a mouse at follow-up after treatment with L-NAME and spironolactone. The dashed line corresponds to the standard method of determining ECV from the ratio of the change of R1 in myocardial tissue divided by the change of R1 in blood (a linear model). At higher contrast concentrations the myocardial R1 increases more slowly than predicted by this linear model, because the exchange of water across the sarcolemmal membrane becomes the rate-limiting step for myocardial relaxation, thereby resulting in a myocardial R1 that is lower than expected for fast exchange conditions (double arrow). ECV and intracellular lifetime were determined by a 2-space model of water exchange across the (sarcolemmal) membrane between the 2 spaces. ECV indicates extracellular volume; L-NAME, No−nitro-L-arginine-methyl-ester.

**Figure 2.** The extracellular volume fraction (ECV) increased with the build-up of interstitial fibrosis in the mice treated with L-NAME, compared to L-NAME+spironolactone. At baseline there were no significant differences in ECV between controls ("placebo"), L-NAME, and L-NAME+spironolactone groups. The ECV data for the control group are from a previous study, using the same experimental protocol. At follow-up ECV was not significantly different between controls and L-NAME+spironolactone ($p=0.48$). L-NAME indicates No−nitro-L-arginine-methyl-ester.
spironolactone prevents fibrosis and hypertrophy

Coelho-Filho et al.

antagonist therapy with spironolactone on L-NAME-induced hypertrophy (an early occurrence in pressure overload) is absent. The ability to look at cardiomyocyte hypertrophy (an early occurrence in pressure overload) is absent.

Accordingly, we studied the effect of mineralocorticoid antagonist therapy with spironolactone on L-NAME-induced hypertensive heart disease, demonstrating abrogation of interstitial fibrosis, cardiomyocyte hypertrophy, and whole-organ LVH when spironolactone was initiated at the time of L-NAME. Extending our previous report in this model,16,22 we demonstrate for the first time that dynamic changes in myocardial ECV and τlc with spironolactone are highly associated with coordinate histological changes within the myocardium. These results establish ECV and τlc as noninvasive, modifiable indices of tissue-level changes within the heart relevant to pre-clinical HF. Although small studies have demonstrated reduction in collagen turnover with mineralocorticoid antagonism in HF-pEF,42 myocardial ECV provides an accurate reflection of the expansion of the extra-cellular space due to the aggregate collagen accumulation – not turnover – within the heart, likely more specific to the underlying substrate for ventricular stiffness and clinical HF.

Our results are timely in the context of increasing attention on the role of mineralocorticoid (MR) antagonist therapy in HF-pEF.8 MR antagonist therapy reduces interstitial fibrosis and cellular hypertrophy in animal models, improving ventricular performance and survival independent of blood pressure lowering or serum aldosterone concentration.9,43 In the largest published clinical study of spironolactone in HF-pEF, Edelmann and colleagues reported a reduction of LV mass with slight improvement in echocardiographic diastolic dysfunction with spironolactone; unfortunately, this did not translate to improvement in functional capacity.5,37 In small studies, circulating markers of myocardial fibrosis are reduced with MR antagonism.42 Given the complex, life-long exposure to profibrotic comorbidities that track closely with HF-pEF (eg, hypertension, diabetes, obesity), these results suggest that true benefits of MR antagonism may be realized with preventative application earlier in the course of disease, before irreversible interstitial fibrosis has taken hold. In this light, the prevalence and reversibility of an aberrant myocardial tissue phenotype by CMR demonstrated here provides a backdrop for future investigations in antifibrotic therapies at an earlier stage of disease, possibly allowing the direct observation of therapeutic efficacy before frank LV dysfunction, hypertrophy, or HF. In this context, we eagerly await the results of TOPCAT (Treatment of Preserved Cardiac Function after Heart Failure with an Aldosterone Antagonist study; clinical trials identifier NCT00094302).8

Our results should be viewed in the context of study design. Although we do not have spironolactone drug levels to confirm efficacy, we observe a lower average blood pressure with spironolactone. While we do not measure reversibility of established fibrosis, our demonstration of the modifiability of myocardial ECV and τlc is the first, essential step in determining a “threshold” beyond which MR antagonism fails to affect the heart. In addition, the placebo-treated controls used in this study were previously published and not imaged.

Figure 3. The intracellular lifetime of water (τlc), a measure of cardiomyocyte diameter, increased significantly in the mice treated with L-NAME, compared to L-NAME+spironolactone, consistent with the histological appearance of cardiomyocyte hypertrophy. At baseline there was no significantly difference in τlc between controls, L-NAME, and L-NAME+spironolactone groups. The τlc data for the control group are from a previous study, using the same experimental protocol. At follow-up, τlc in the L-NAME+spironolactone group was not significantly different from controls (P=0.34). L-NAME indicates N-nitro-L-arginine-methyl-ester.
concurrently with L-NAME-treated mice; however, given the large experience with normal mice, there is no systematic reason why concurrent imaging would yield different results. Finally, more detailed assessments of diastolic function (eg, CMR tagging), HF (via lung-heart weight), or changes in myocardial stiffness (eg, by invasive pressure-volume loop analysis) were not performed in this study. However, prevention of fibrosis with spironolactone (versus L-NAME alone) with a preserved LVEF suggests that spironolactone normalized the structural myocardial phenotype.

The measurements of ECV and $\tau_{ic}$ reported in this study relied on multiple (4 to 5) measurements of T1 after contrast injection. This is more time-consuming than protocols utilized in previous studies for determination of ECV alone, which generally rely on two T1 measurements (1 pre- and 1 post-contrast). The shorter protocol based on 2 T1 measurements assumes that the exchange of water across the sarcolemmal membrane (described by the intracellular lifetime of water $\tau_{ic}$) is negligible. For determination of $\tau_{ic}$, it is necessary to measure T1 when fast water exchange conditions no longer apply in order to observe an effect from the finite intracellular lifetime. The model for fitting the change of the myocardial R1 as a function of R1 in blood has both ECV and $\tau_{ic}$ as adjustable parameters and requires multiple postcontrast measurements for a reliable estimation of $\tau_{ic}$. A further limitation is the fact that in myocardial tissue, cardiomyocytes account for approximately 90% of the intracellular volume, meaning the measured intracellular lifetime of water will have some slight bias from the contribution of other cell types.

To our knowledge, our results are the first noninvasive demonstration that a comprehensive myocardial tissue phenotype quantifying cardiomyocyte hypertrophy and interstitial fibrosis are variable with therapy in a model of pressure overload. These results extend the use of CMR to detect early disease myocardial changes into a therapeutic realm: the ability to noninvasively phenotype tissue-based LV remodeling.
Figure 5. The extra-cellular volume fraction (ECV) of myocardial tissue (A), and the intracellular lifetime of water (τic; B), both determined by cardiac magnetic resonance T1 measurements, correlated strongly with the corresponding histological measures, namely the connective tissue fraction on tissue slices stained with Masson’s trichrome, and the cardiomyocyte diameters obtained from morphometric analysis of tissues slices in which the cell membranes were highlighted with wheat germ agglutinin. If the previously published data from a placebo-treated group are included the correlations are 0.89 for (A), and 0.86 for (B). In (A) and (B) the solid line represents the least squares estimator of a linear regression model of MR derived measure (ECV or τic) as a function of corresponding histological measure, and the dashed lines represent the 95% confidence limits for the linear estimates. L-NAME indicates Nω-nitro-L-arginine-methyl-ester; MR, mineralocorticoid receptor.

with therapy – otherwise inaccessible markers early in the development of HF – is fundamental to furthering our understanding of pathobiology of HF and its reversal.

Acknowledgments
We would like to thank Deborah Burstein, PhD, director of the Beth Israel Deaconess Small Animal Imaging Facility, and Reza Akhavan, MS, for their support.

Sources of Funding
The Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL090634. Drs Coelho-Filho and Shah are supported by Post-Doctoral Fellowships from the American Heart Association (AHA 11POST5550053 to OCF and AHA 11POST110033 to RVS). Dr Neilan is supported by an American Heart Association Fellow-to-Faculty grant (12FTF12060588).

Disclosures
None.

References


